脓毒症合并急性肾损伤患者连续性肾脏替代治疗剂量的选择  

Dose optimization of continuous renal replacement therapy in sepsis-induced acute kidney injury

作　　者：崔俊[1] 周峻峰[1] 万献尧[1] 

机构地区：[1]大连医科大学附属第一医院重症医学科,辽宁大连116011

出　　处：《中华危重病急救医学》2016年第10期957-960,共4页Chinese Critical Care Medicine

基　　金：辽宁省自然科学基金（201102053）;辽宁省医药卫生项目（ZX201003）;中华医学会临床医学科研专项（10030140236）;辽宁省大连市科技计划项目（2012E15SF162）

摘　　要：脓毒症是宿主对感染的反应失调，导致危及生命的器官功能损害，由脓毒症导致的急性肾损伤（AKI）发生率和病死率均较高，且预后不良。连续性肾脏替代治疗（CRRT）是目前治疗合并AKI的重症患者不可或缺的手段，但有关CRRT的合适治疗剂量目前尚无一致意见。通过回顾高容量血液滤过（HVHF）与标准剂量血液滤过（SVHF）的提出与应用历程，对两者的获益及风险进行对比，并对治疗方案提出可改进意见，为临床工作提供依据。Sepsis is a life-threatening organ dysfunction caused by dys-regulated host response to infection. Acute kidney injury （AKI） caused by sepsis is one of the most common and severe clinical disease, which incidence and mortality remains high level, and has poor clinical outcomes. Continuous renal replacement therapy （CRRT） is an indispensable tool for the treatment of critically ill patients with severe AKI, but there is no consensus on the appropriate treatment dose of CRRT. By reviewing the process of high volume hemofiltration （HVHF） and standard volume hemofiltration （SVHF）, comparing their benefits and risks, and making suggestions for therapeutic schedule improvement, reference for clinical work was provided.

关 键 词：高容量血液滤过 标准剂量血液滤过 脓毒症 

分 类 号：R459.7[医药卫生—急诊医学] R692.5[医药卫生—治疗学]